CompletedNCT01452919
Dependence Symptoms After Stopping LY2140023 in Schizophrenia
About this title
Read the official source — NCT01452919Medication studyAges 18–65United States + Greece
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Oakland and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 123
- Sponsor
- Denovo Biopharma LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Greece
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01452919
- Official title
Show the full official title
A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Oakland, United States · San Diego, United States · Torrance, United States
7 more locations
- North Miami, United States
- Lake Charles, United States
- Flowood, United States
- Philadelphia, United States
- Bellevue, United States
- Chaïdári, Greece
- Tripoli, Greece
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Denovo Biopharma LLC.
Did this study involve medication?
Yes. The study involved medication, including LY2140023 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
